High impact
Temozolomide (Temodar®)
BCBS Tennessee·Effective Sep 30, 2026
BlueCross BlueShield of Tennessee has issued a new medical policy for Temozolomide (Temodar®) establishing coverage criteria for 12+ FDA-approved and compendial oncology indications, including glioblastoma, anaplastic astrocytoma, neuroendocrine tumors, sarcomas, melanomas, and others. The policy requires prior authorization for all covered uses and specifies therapy line requirements and combination therapy rules. This policy is NOT YET EFFECTIVE and must not be implemented until September 30, 2026.